Efficacy and Safety of Intratumoral Injection of Recombinant Human Adenovirus Type 5 Combined With Tislelizumab and Lenvatinib in the Treatment of Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma Clinical Trial

Official title:

Efficacy and Safety of Intratumoral Injection of Recombinant Human Adenovirus Type 5 Combined With Tislelizumab and Lenvatinib in the Treatment of Advanced Hepatocellular Carcinoma: a Single-center, Prospective, Single-arm Study

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06253598
• Other study ID #: HCC-01
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: March 30, 2024
• Est. completion date: December 30, 2026

Study information

• Verified date: February 2024
• Source: First Affiliated Hospital Bengbu Medical College
• Contact: Wang Zishu, Doctor
• Phone: +8618909620171
• Email: wzshahbb[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This prospective, single-arm study was aimed to evaluate the efficacy of recombinant human adenovirus type 5 injection combined with tislelizumab and lenvatinib in the treatment of advanced hepatocellular carcinoma. The recombinant human adenovirus type 5 was administered intratumorally on day 1 and 5 in cycle 1 and cycle 2. Lenvatinib was administered orally once daily started on day 1 of cycle 1 .Tislelizumab was administered intravenously every 3 week started on day 1 of cycle 3. The patient accepted the therapy until disease progression or unacceptable toxicity occurred or meet the end point of the study. The primary end point was ORR assessed by investigator using RECIST v1.1 .

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 30
• Est. completion date: December 30, 2026
• Est. primary completion date: December 30, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Age =18 years old, and =75 years old, regardless of gender;

2. Primary hepatocellular carcinoma confirmed by histology or imaging;

3. Patients with advanced hepatocellular carcinoma who have not received oncolytic viruses, immutherapy drugs (including anti-PD-1, anti-PD-L1, or anti-PD-L2 drugs), and systemic therapy (such as anti-VEGF /VEGFR monoclonal antibodies, anti- VEGFR-TKI drugs, chemotherapy);

4. ECOG performance status 0-1;

5. Child-Pugh score =7;

6. There was at least one measurable target lesion according to RECIST 1.1 criteria, and at least one lesion was = 10 mm;

7. The expected survival time was =3 months;

8. Laboratory tests during the screening period met the following criteria:

i. White blood cell count = 3.0×10^9 /L, absolute neutrophil count =1.5×10^9/L, platelet count = 75×10^9/L, hemoglobin > 90g/L

ii. INR=1.5 and APTT=1.5 times upper limit of normal or partial prothrombin time (PTT) =1.5 times upper limit of normal;

iii. Total bilirubin =2.5 times upper limit of normal; ALT and AST=5 times upper limit of normal (ULN); Serum creatinine =1.5 times the upper limit of normal.

9. They volunteered to participate in this study and signed informed consent.

Exclusion Criteria:

1. Pregnant or lactating women, men or women unwilling to use effective contraception;

2. Diffuse liver cancer or tumor is not suitable for RECIST 1.1 criteria;

3. Patients who have previously received an oncolytic viral agent such as T-VEC;

4. Known allergy to the study drug or its active ingredient, history of allergy to the same biological agent;

5. HBV DNA quantitation =1000 copies.

6. Imaging showed portal vein tumor thrombus more than half of the lumen, inferior vena cava tumor thrombus or heart involvement.

7. The patient has had grade =2 hepatic encephalopathy within 12 months or currently requires medication to prevent or control hepatic encephalopathy.

8. Confirmed active tuberculosis (TB), known human immunodeficiency virus (HIV) positive patients, and other serious infections requiring treatment;

9. A history of immunodeficiency or autoimmune disease, or long-term systemic steroid therapy or any form of immunosuppressive therapy within 7 days before enrollment;

10. A history of other (including unknown primary) malignancies, except for Cured non- melanoma skin malignancies, carcinoma in situ of the cervix, radical stage I uterine cancer, radical ductal carcinoma in situ or lobular carcinoma in situ of the breast (without any systemic treatment), localized prostate cancer that is currently considered cured after radical surgery, and other solid tumors that have been treated with radical surgery for more than 5 years without evidence of recurrence;

11. Known tumors of the central nervous system, including metastatic brain tumors;

12. Accompanied by any unstable systemic disease, including but not limited to: Severe infections, patients with hypertension whose blood pressure cannot be lowered to normal after antihypertensive treatment, uncontrolled diabetes mellitus, unstable angina pectoris, cerebrovascular accident or transient ischemic attack, myocardial infarction (a history of myocardial infarction of 6 months or more is allowed), congestive heart failure, serious arrhythmias requiring medical treatment, renal or metabolic diseases;

13. With medical contraindications to any contrast-enhanced imaging (CT or MRI);

14. Participants who had participated in an interventional clinical trial within 30 days before screening (Note: Participants who were already in the follow-up phase of the clinical trial could participate in this trial if it was 4 weeks after the last dose of the previous investigational drug).

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Hepatocellular
• Hepatocellular Carcinoma

Intervention

Drug:
• Recombinant Human Adenovirus Type 5
Recombinant Human Adenovirus Type 5( H101 )was administered intratumorally on day 1 and 5 of cycle 1 and cycle 2. If the sum of the maximum diameters of the lesions was less than or equal to 10 cm, the total dose was 1.0×10^12 vp . If the sum of the maximum diameters of the lesions was more than 10 cm, the total dose was 1.5×10^12 vp. Recombinant Human Adenovirus Type 5 was diluted to 30% of the total tumor volume with normal saline before administration. Under the guidance of ultrasound, percutaneous puncture was performed to the center of the tumor, and the solution was uniformly injected into the tumor. If there are multiple lesions, the distribution of each lesion should be proportional to the size of the tumor. No more than 5 lesions.
• Lenvatinib
Lenvatinib was administered orally once daily started on day 1 of cycle 1 of the study until disease progression or unacceptable toxicity occurred or meet the end point of the study. For patients weighing less than 60 kg, the recommended daily dose was 8 mg once daily. For patients weighing =60 kg, the recommended daily dose was 12 mg once daily
• Tislelizumab
Tislelizumab 200mg was administered intravenously every 3 week started on day 1 of cycle 3 until disease progression or unacceptable toxicity occurred or meet the end point of the study.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
First Affiliated Hospital Bengbu Medical College

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Objective response rate using RECIST v1.1	ORR is defined as the proportion of patients who have a partial or complete response to therapy	3 years
Secondary	DOT	Duration of treatment	3 years
Secondary	DOR	Duration of response	3 years
Secondary	DCR	Disease control rate	3 years
Secondary	PFS	progression-free survival	3 years
Secondary	1-year overall survival rate	the overall survival rate at 1 year	1years
Secondary	AE	adverse events base on CTCAE v5.0	3 years